The relatively higher ORR observed in CLDN18.2-targeted therapy compared to other studies may be partially explained by recent findings that CLDN18 promotes cytotoxic T-lymphocyte accumulation by facilitating direct T-cell-tumor cell interactions through mobilization of the adhesion protein ALCAM into tumor cell membrane lipid rafts [58]. Here, ALCAM is linked to neoplasm.